Please use this identifier to cite or link to this item:
|Title:||Prediction of synergistic antitumour effect of gefitinib and radiation in vitro.|
|Publisher:||The International Institute of Anticancer Research|
|Citation:||Lin, H. Q., Meriaty, H., & Katsifis, A. (2011). Prediction of synergistic antitumour effect of gefitinib and radiation in vitro. Anticancer Research, 31(9), 2883-2888. Retrieved from http://ar.iiarjournals.org/content/31/9/2883.full|
|Abstract:||AIM: This study investigated the potential of a series of biomarkers in predicting the interaction of gefitinib and radiation in tumour treatment. MATERIALS AND METHODS: In vitro assays were performed on human skin cancer and melanoma cell lines. The antitumour effect was measured by using the MTT assay. Total and phosphorylated epidermal growth factor receptor (EGFR and pEGFR) levels were determined by cell-based ELISA. RESULTS: Gefitinib and radiation interacted to inhibit tumour cell proliferation in a cell line-dependent manner. Synergism dominated the interaction (76%), followed by additive effect (20%) and a few instances of antagonism (4%). Correlation analyses revealed a significant correlation between the median combination index (CI) and gefitinib IC950), radiation ID(50, gefitinib- or EGF-modulated EGFR and/or pEGFR expression (all p ≤ 0.05). CONCLUSION: A potential role of gefitinib efficacy, radiation efficacy and gefitinib- or EGF-modulated EGFR and/or pEGFR expression in the prediction of interaction between gefitinib and radiation is supported. Copyright © 2011 The International Institute of Anticancer Research.|
|Gov't Doc #:||5293|
|Appears in Collections:||Journal Articles|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.